The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys

European Journal of Pharmacology

Volumn 415, Issue 1, 2001, Pages 79-84

  Van Heek, Margaret ^a   Compton, Douglas S ^a   Davis, Harry R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

(Rhesus monkey); Apo B100; Apo B48; Chylomicron; Cynomolgus monkey; LDL (low density lipoprotein); Postprandial

Indexed keywords

1,4 BIS(4 METHOXYPHENYL) 3 (3 PHENYLPROPYL) 2 AZETIDINONE; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHOLESTEROL; CHYLOMICRON; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; MALE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RHESUS MONKEY; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CHOLESTEROL ESTERS; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPERCHOLESTEROLEMIA; MACACA FASCICULARIS; MACACA MULATTA; MALE; TIME FACTORS; TRIGLYCERIDES;

EID: 0035831089     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00825-1     Document Type: Article

References (21)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The clinical development of a novel cholesterol absorption inhibitor
3. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
4. Postprandial lipoprotein metabolism and atherosclerosis
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH58235): Pooled analysis of two Phase II studies
7. Atherosclerosis as a post-prandial disease
8. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels
9. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study
10. Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk
11. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)- (4-hydroxyphenyl)-2-azetidinone (SCH58235): A designed, potent, orally active inhibitor of cholesterol absorption
12. Determination of cholesterol using o-phthalaldehyde
13. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
14. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461
15. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
16. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death
17. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
18. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
19. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients
20. Atherogenesis: A postprandial phenomenon
21. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins